Nature's TRAIL - On a path to cancer immunotherapy

Immunity

Volumn 18, Issue 1, 2003, Pages 1-6

  Smyth, Mark J ^d   Takeda, Kazuyoshi ^b   Hayakawa, Yoshihiro ^a   Peschon, Jacques J ^c   Van Den Brink, Marcel R M ^d   Yagita, Hideo ^b  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c AMGEN INC   (United States)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ALLOGENIC BONE MARROW TRANSPLANTATION; ANTINEOPLASTIC ACTIVITY; CANCER IMMUNOTHERAPY; CANCER THERAPY; HUMAN; IMMUNOSURVEILLANCE; MOLECULE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; SHORT SURVEY; T LYMPHOCYTE; TUMOR; TUMOR CELL;

EID: 0037240850     PISSN: 10747613     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1074-7613(02)00502-2     Document Type: Short Survey

References (37)

1. Ashkenazi A. Targeting death and decoy receptors of the tumour-necrosis factor superfamily. Nat. Rev. Cancer. 2:2002;420-430.
2. Ashkenazi A., Dixit V.M. Death receptors. signaling and modulation Science. 281:1998;1305-1308.
3. Ashkenazi A., Pai R.C., Fong S., Leung S., Lawrence D.A., Marsters S.A., Blackie C., Chang L., McMurtrey A.E., Hebert A.et al. Safety and antitumor activity of recombinant soluble Apo2 ligand. J. Clin. Invest. 104:1999;155-162.
4. Bodmer J.L., Holler N., Reynard S., Vinciguerra P., Schneider P., Juo P., Blenis J., Tschopp J. TRAIL receptor-2 signals apoptosis through FADD and caspase-8. Nat. Cell Biol. 2:2000;241-243.
5. Burns T.F., El-Deiry W.S. Identification of inhibitors of TRAIL-induced death (ITIDs) in the TRAIL-sensitive colon carcinoma cell line SW480 using a genetic approach. J. Biol. Chem. 276:2001;37879-37886.
6. Cretney E., Takeda K., Yagita H., Glaccum M., Peschon J.J., Smyth M.J. Increased susceptibility to tumor initiation and metastasis in TNF-related apoptosis-inducing ligand-deficient mice. J. Immunol. 168:2002;1356-1361.
7. Degli-Esposti M. To die or not to die-the quest of the TRAIL receptors. J. Leukoc. Biol. 65:1999;535-542.
8. Deng Y., Lin Y., Wu X. TRAIL-induced apoptosis requires Bax-dependent mitochondrial release of Smac/DIABLO. Genes Dev. 16:2002;33-45.
9. El-Deiry W.S. Insights into cancer therapeutic design based on p53 and TRAIL receptor signaling. Cell Death Differ. 8:2001;1066-1075.
10. Fanger N.A., Maliszewski C.R., Schooley K., Griffith T.S. Human dendritic cells mediate cellular apoptosis via tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). J. Exp. Med. 190:1999;1155-1164.
11. Griffith T.S., Wiley S.R., Kubin M.Z., Sedger L.M., Maliszewski C.R., Fanger N.A. Monocyte-mediated tumoricidal activity via the tumor necrosis factor-related cytokine TRAIL. J. Exp. Med. 189:1999;1343-1354.
12. Hersey P., Zhang X.D. How melanoma cells evade trail-induced apoptosis. Nat. Rev. Cancer. 1:2001;142-150.
13. Hilliard B., Wilmen A., Seidel C., Liu T.S., Goke R., Chen Y. Roles of TNF-related apoptosis-inducing ligand in experimental autoimmune encephalomyelitis. J. Immunol. 166:2001;1314-1319.
14. Ichikawa K., Liu W., Zhao L., Wang Z., Liu D., Ohtsuka T., Zhang H., Mountz J.D., Koopman W.J., Kimberly R.P.et al. Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity. Nat. Med. 7:2001;954-960.
15. Kayagaki N., Yamaguchi N., Nakayama M., Eto H., Okumura K., Yagita H. Type I interferons (IFNs) regulate tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) expression on human T cells. a novel mechanism for the antitumor effects of type I IFNs J. Exp. Med. 189:1999;1451-1460. a.
16. Kayagaki N., Yamaguchi N., Nakayama M., Kawasaki A., Akiba H., Okumura K., Yagita H. Involvement of TNF-related apoptosis-inducing ligand in human CD4+ T cell-mediated cytotoxicity. J. Immunol. 162:1999;2639-2647. b.
17. Kayagaki N., Yamaguchi N., Nakayama M., Takeda K., Akiba H., Tsutsui H., Okamura H., Nakanishi K., Okumura K., Yagita H. Expression and function of TNF-related apoptosis-inducing ligand on murine activated NK cells. J. Immunol. 163:1999;1906-1913. c.
18. Lawrence D., Shahrokh Z., Marsters S., Achilles K., Shih D., Mounho B., Hillan K., Totpal K., DeForge L., Schow P.et al. Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions. Nat. Med. 7:2001;383-385.
19. LeBlanc H., Lawrence D., Varfolomeev E., Totpal K., Morlan J., Schow P., Fong S., Schwall R., Sinicropi D., Ashkenazi A. Tumor-cell resistance to death receptor-induced apoptosis through mutational inactivation of the proapoptotic Bcl-2 homolog Bax. Nat. Med. 8:2002;274-281.
20. Nagane M., Huang H.J., Cavenee W.K. The potential of TRAIL for cancer chemotherapy. Apoptosis. 6:2001;191-197.
21. Nguyen T., Zhang X.D., Hersey P. Relative resistance of fresh isolates of melanoma to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis. Clin. Cancer Res. 7:2001;966s-973s.
22. Pitti R.M., Marsters S.A., Ruppert S., Donahue C.J., Moore A., Ashkenazi A. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J. Biol. Chem. 271:1996;12687-12690.
23. Plasilova M., Zivny J., Jelinek J., Neuwirtova R., Cermak J., Necas E., Andera L., Stopka T. TRAIL (Apo2L) suppresses growth of primary human leukemia and myelodysplasia progenitors. Leukemia. 16:2002;67-73.
24. Sato K., Hida S., Takayanagi H., Yokochi T., Kayagaki N., Takeda K., Yagita H., Okumura K., Tanaka N., Taniguchi T.et al. Antiviral response by natural killer cells through TRAIL gene induction by IFN-alpha/beta. Eur. J. Immunol. 31:2001;3138-3146.
25. Schmaltz C., Alpdogan O., Horndasch K.J., Muriglan S.J., Kappel B.J., Teshima T., Ferrara J.L., Burakoff S.J., van den Brink M.R. Differential use of Fas ligand and perforin cytotoxic pathways by donor T cells in graft-versus-host disease and graft-versus-leukemia effect. Blood. 97:2001;2886-2895.
26. Schmaltz C., Alpdogan O., Kappel B.J., Muriglan S.J., Rotolo J.A., Ongchin J., Willis L.M., Greenberg A.S., Eng J.M., Crawford J.M.et al. T cells require TRAIL for optimal graft-versus-tumor activity. Nat. Med. 8:2002;1433-1437.
27. Smyth M.J., Thia K.Y., Street S.E., MacGregor D., Godfrey D.I., Trapani J.A. Perforin-mediated cytotoxicity is critical for surveillance of spontaneous lymphoma. J. Exp. Med. 192:2000;755-760.
28. Smyth M.J., Cretney E., Takeda K., Wiltrout R.H., Sedger L.M., Kayagaki N., Yagita H., Okumura K. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) contributes to interferon gamma-dependent natural killer cell protection from tumor metastasis. J. Exp. Med. 193:2001;661-670.
29. Song K., Chen Y., Goke R., Wilmen A., Seidel C., Goke A., Hilliard B. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is an inhibitor of autoimmune inflammation and cell cycle progression. J. Exp. Med. 191:2000;1095-1104.
30. Street S.E., Cretney E., Smyth M.J. Perforin and interferon-gamma activities independently control tumor initiation, growth, and metastasis. Blood. 97:2001;192-197.
31. Takeda K., Hayakawa Y., Smyth M.J., Kayagaki N., Yamaguchi N., Kakuta S., Iwakura Y., Yagita H., Okumura K. Involvement of tumor necrosis factor-related apoptosis-inducing ligand in surveillance of tumor metastasis by liver natural killer cells. Nat. Med. 7:2001;94-100.
32. Takeda K., Smyth M.J., Cretney E., Hayakawa Y., Kayagaki N., Yagita H., Okumura K. Critical role for tumor necrosis factor-related apoptosis-inducing ligand in immune surveillance against tumor development. J. Exp. Med. 195:2002;161-169.
33. Walczak H., Miller R.E., Ariail K., Gliniak B., Griffith T.S., Kubin M., Chin W., Jones J., Woodward A., Le T.et al. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat. Med. 5:1999;157-163.
34. Wiley S.R., Schooley K., Smolak P.J., Din W.S., Huang C.P., Nicholl J.K., Sutherland G.R., Smith T.D., Rauch C., Smith C.A.et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity. 3:1995;673-682.
35. Wu G.S., Kim K., el-Deiry W.S. KILLER/DR5, a novel DNA-damage inducible death receptor gene, links the p53-tumor suppressor to caspase activation and apoptotic death. Adv. Exp. Med. Biol. 465:2000;143-151.
36. Wuchter C., Krappmann D., Cai Z., Ruppert V., Scheidereit C., Dorken B., Ludwig W.D., Karawajew L. In vitro susceptibility to TRAIL-induced apoptosis of acute leukemia cells in the context of TRAIL receptor gene expression and constitutive NF-kappa B activity. Leukemia. 15:2001;921-928.
37. Zamai L., Ahmad M., Bennett I.M., Azzoni L., Alnemri E.S., Perussia B. Natural killer (NK) cell-mediated cytotoxicity. differential use of TRAIL and Fas ligand by immature and mature primary human NK cells J. Exp. Med. 188:1998;2375-2380.